Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Candel Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CADL
Nasdaq
2830
www.candeltx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Candel Therapeutics, Inc.
Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment
- Jan 18th, 2025 12:21 pm
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
- Jan 13th, 2025 1:00 pm
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
- Jan 9th, 2025 6:44 am
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Dec 16th, 2024 9:01 pm
Top Midday Decliners
- Dec 13th, 2024 6:41 pm
Sector Update: Health Care Stocks Steady Premarket Friday
- Dec 13th, 2024 2:17 pm
Candel Therapeutics Announces Pricing of Public Offering
- Dec 13th, 2024 4:00 am
Candel Therapeutics Announces $80 Million Proposed Public Offering
- Dec 12th, 2024 9:51 pm
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
- Dec 12th, 2024 3:31 pm
Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug
- Dec 11th, 2024 9:09 pm
Candel Therapeutics Prostate Cancer Therapy Shows Promise
- Dec 11th, 2024 6:07 pm
Candel Therapeutics stock up 172% after Phase III prostate cancer success
- Dec 11th, 2024 3:32 pm
Candel Therapeutics Stock Surges Over 100% - Here's Why
- Dec 11th, 2024 2:19 pm
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
- Dec 11th, 2024 12:00 pm
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Nov 14th, 2024 1:00 pm
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
- Nov 7th, 2024 1:00 pm
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
- Nov 5th, 2024 2:00 pm
Candel Therapeutics Advances in Cancer Treatment Trials
- Oct 29th, 2024 12:59 pm
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
- Oct 28th, 2024 12:00 pm
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
- Oct 4th, 2024 1:00 pm
Scroll